Statins downregulate myeloperoxidase gene expression in macrophages.

Area of Science:

• Biochemistry
• Immunology
• Cardiovascular Research

Background:

• Statins offer benefits beyond cholesterol reduction, including antioxidant and anti-inflammatory effects.
• Myeloperoxidase (MPO) in macrophages oxidizes ApoA-1, hindering cholesterol efflux and correlating with coronary artery disease (CAD) risk.

Purpose of the Study:

• To investigate the impact of statins on myeloperoxidase (MPO) expression.
• To elucidate the molecular mechanisms underlying statin-mediated MPO suppression.

Main Methods:

• Assessed MPO mRNA expression in human and murine monocyte-macrophages treated with statins.
• Investigated the role of HMG-CoA reductase intermediates (mevalonate, geranylgeranylpyrophosphate, farnesylpyrophosphate) and a geranylgeranyltransferase inhibitor (GGTI-286).
• Evaluated MPO mRNA, protein, and enzyme activity in leukocytes from statin-fed mice.

Main Results:

• Statins strongly inhibited MPO mRNA expression in macrophages.
• MPO suppression was reversed by mevalonate and geranylgeranylpyrophosphate, but not farnesylpyrophosphate.
• Inhibition of geranylgeranylation mimicked statin effects, implicating this pathway.
• In vivo studies showed reduced MPO mRNA, protein, and activity in statin-treated mice leukocytes.

Conclusions:

• Statins suppress MPO expression through a mechanism involving geranylgeranylation.
• Reduced MPO expression may contribute to the pleiotropic, cardioprotective effects of statins.
• Targeting MPO could be a novel therapeutic strategy for cardiovascular disease.